Skip to main content
    A

    Adaptive Biotechnologies Corp (ADPT)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $27.87
    -1.17 (-4.03%)

    Market Cap: $4.70B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Adaptive Biotechnologies Corp (ADPT) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Adaptive Biotechnologies (ADPT) to earn -$0.37 per share in the fiscal year ending Dec 31, 2026, on revenue of $307.02M. Of 8 analysts, 8 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 1.75, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy225.0%
    Buy675.0%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    8

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 21.6%.

    Fiscal year ending Dec 31, 2026
    -$0.37
    EPS consensus, revenue $307.02M
    Fiscal year ending Dec 31, 2027
    -$0.03
    EPS consensus, revenue $373.34M
    Next report
    Feb 3, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.37-$0.37 to -$0.371$307.02M$304.32M to $309.68M7
    Dec 31, 2027-$0.03-$0.08 to -$0.013$373.34M$360.00M to $388.81M8

    Quarterly Estimates

    The EPS consensus falls from -$0.07 for the quarter ending Dec 31, 2026 to -$0.10 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.07-$0.08 to -$0.0411$82.13M$76.44M to $87.15M10
    Mar 31, 2027-$0.10-$0.10 to -$0.102$80.41M$77.71M to $82.80M7

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 5 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202730
    Quarter ending Mar 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.54.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.37-$0.54-$0.54-$0.54-$0.54N/A
    Fiscal year ending Dec 31, 2027-$0.03-$0.18-$0.18-$0.18-$0.18N/A
    Quarter ending Mar 31, 2027-$0.10-$0.10-$0.10-$0.10-$0.10N/A

    Frequently Asked Questions About ADPT

    What is the ADPT stock forecast?

    Consensus analyst estimates put Adaptive Biotechnologies's EPS at -$0.37 for the fiscal year ending Dec 31, 2026, on revenue of $307.02M. The consensus rating from 8 analysts is Buy.

    How do analysts rate ADPT stock?

    Of 8 analysts covering Adaptive Biotechnologies, 2 rate it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from ADPT next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.37, with estimates from -$0.37 to -$0.37 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.03, with estimates from -$0.08 to -$0.01 from 3 analysts.

    What revenue do analysts expect from Adaptive Biotechnologies next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $307.02M, with estimates from $304.32M to $309.68M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $373.34M, with estimates from $360.00M to $388.81M.

    How many analysts cover ADPT?

    8 analysts rate Adaptive Biotechnologies stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.